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Lung cancer stagingAbstract Background: CRP is an inﬂammatory mediator that is shown to be elevated in different
inﬂammatory and malignant conditions, the aim of the study to see whether the elevated serum
CRP is correlated with the advanced stages and increased tumor size of NSCLC after exclusion
of patients with high CRP due to infection.
Materials and methods: 71 patients with proved NSCLC and 25 healthy control volunteers were
selected for the study, serum CRP and PCT were analyzed, results of CRP in patients with NSCLC
were compared with the control group, and subgroups were made according to different clinical
variables as subtypes of lung cancer, tumor staging and tumor size.
Results: The serum CRP level was signiﬁcantly higher in patients with NSCLC compared to the
control group 114.2 ± 60.1 mg/ml vs. 13.4 ± 8.6 mg/ml) with p value <0.001, no signiﬁcant
difference was recorded in PCT level (p> 0.05), there was no signiﬁcant difference between
NSCLC subtypes (p> 0.05), there was a positive correlation between CRP level and tumor size
(p< 0.01), TNM tumor staging (p< 0.01).
Conclusion: CRP is an inﬂammatory biomarker that is shown to be elevated in NSCLC and its
elevation is correlated with the tumor size and tumor staging but not to subtypes of NSCLC, it may
point to poor outcome and poorer prognosis.
ª 2014 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis.Open access under CC BY-NC-ND license.Introduction
C-reactive protein (CRP) was discovered in 1930 and is widely
used as a sensitive, but nonspeciﬁc, marker of systemicinﬂammation [1]. C-reactive protein (CRP) is the prototype
acute-phase protein, which can increase up to 1000-fold after
the onset of a stimulus. Aside from its disputed role as a mar-
ker of infection and/or inﬂammation in daily clinical practice,
the protein has a wide variety of biological properties and
functions [2]. Increased serum CRP (s-CRP) levels have been
reported in many pulmonary disorders, including pneumonia,
malignancies, and pulmonary thromboembolism [3].
The elevated levels of CRP are associated with an increased
risk of all-cancer, lung cancer, and possibly breast, prostate
and colorectal cancer [4]. And it is positively correlated with
weight loss, anorexia-cachexia syndrome, extent of disease,
and recurrence in advanced cancer [5].
718 H. Aref, S. RefaatThe reasons for CRP elevation in cancer patients are not
clearly understood, several possible mechanisms have been
proposed for the relationship between CRP and cancer [6].
Some stated that tumor cells themselves cause tissue inﬂamma-
tion and thus increase CRP levels, and the presence of Malig-
nant Pleural Effusion usually indicates the severity of illness
and a short survival time [7].
One possible explanation is that, due to cytokine produc-
tion by tumor tissue, elevated CRP values may indicate a high-
er tumor burden [6]. Of the cytokines that has been implicated
as the cause of increased CRP production is IL-6 [8].The cat-
abolic effect of acute-phase proteins like CRP on metabolism,
and this is associated with an increase in resting energy expen-
diture and loss of lean tissue in patients with lung cancer [9].
Another reason for elevated CRP may be a cancer-related
infection, particularly a post-stenotic pulmonary infection in
the case of lung tumors. It is well known that pneumonia
may be the ﬁrst sign that marks lung cancer [10]. In cases of
lung cancer CRP may be falsely elevated as a result of infec-
tions that are encountered during the course of disease and in-
crease the incidence of morbidity and mortality [11].
In patients with non-small cell lung cancer (NSCLC), ele-
vated CRP levels prior to therapy have been shown to have
an adverse impact on prognosis [12].
Procalcitonin (PCT), a precursor of the hormone calcito-
nin, participates in the systemic reaction in response to the cir-
culating endotoxins and inﬂammatory cytokines produced
during bacterial or fungal infections. Its plasma levels are cor-
related with the severity of infection [13]. Procalcitonin has
been shown to be important in the differential diagnosis of
cancer patients with fever and high CRP levels [14].
The aim of our study is to correlate the level of CRP to
TNM classiﬁcation of NSCLC cases and also tumor size after
exclusion of cases with high CRP due to bacterial infection or
sepsis detected by analyzing the serum procalcitonin level.Subjects and methods
Patients who were newly diagnosed with NSCLC lung cancer
in the period from July 2010 to January 2013 were included
in this prospective study (71 patients) and 25 of apparently
healthy volunteers were set as a control group, exclusion
criteria were patients diagnosed with small cell lung cancer,
patients under chemotherapy, radiation therapy or any history
of either, use of anti-inﬂammatory drugs or systemic steroids,
presence of inﬂammatory disease or sepsis that could alter the
results of CRP by detecting a high procalcitonin (PCT) level
(above 0.5 ng/ml), patients with high PCT may be re-enrolled
after treatment of their infection or inﬂammation. All of the
recruited patients and volunteers provided written informed
consent.
All patients and control group were evaluated by thorough
history taking including age, sex, body mass index (BMI) and
concomitant diseases of the patients were recorded, complete
physical examination followed by chest X-ray and chest CT
scans where radiological assessment of lung cancer staging
was done using TNM classiﬁcation and also the maximum can-
cer diameter was assessed and calculated, pulmonary function
testing together with routine laboratory testing. In the patient
group diagnosis was made either by bronchoscopic biopsies in
accessible lesions, transthoracic needle biopsy in peripherallesions, pleural ﬂuid aspiration in cases of concomitant
malignant pleural effusion, excisional lung biopsies in cases
not accessible by bronchoscopy or transthoracic route, trans-
bronchial needle aspiration from subcarinal lymph nodes
was done for the diagnosis and staging if subcarinal LN size
is larger than 1 cm, all patients were subjected to MRI brain
abdominal CT scan and bone scintigraphy for an accurate
assessment of distant metastases, after full investigation the
TNM classiﬁcation of each patient was recorded and serum
CRP was analyzed together with serum procalcitonin.
Peripheral venous blood was obtained under sterile condi-
tions both in patients with a conﬁrmed histological diagnosis
of NSCLC and the healthy controls. Serum was separated by
centrifuging for 10 min at 1000g and 4 C in vacuum gel tubes,
and then kept at –80 C in Eppendorf tubes until the time of
assay. All samples were assayed on the same day. CRP was
analyzed by routine clinical laboratory test protocols using
an automated chemical analyzer (Modular P800; Roche
Diagnostics GmbH, Mannheim, Germany).
The serum level of PCT was measured by using an enzyme
linked ﬂuorescence assay (VIDAS BRAHMS PCT assay;
Biome´rieux, Lyon, France) according to the manufacturer’s
instructions and serum CRP levels were assayed by
nephelometry using an automated system (Dade Behring).
Statistical analysis
Data were statistically described in terms of mean (standard
deviation (SD), median and range, or frequencies (number of
cases) and percentages when appropriate. Comparison of
numerical variables between the study groups was done using
Student t test for independent samples in comparing 2 groups
when normally distributed and Mann Whitney U test for inde-
pendent samples when not normally distributed. Comparison
of numerical variables between more than two groups was done
using Kruskal Wallis test. For comparing categorical data, Chi
square (v2) test was performed. Exact test was used instead
when the expected frequency is less than 5. Accuracy was rep-
resented using the terms sensitivity, and speciﬁcity. Receiver
operator characteristic (ROC) analysis was used to determine
the optimum cut off value of CRP in diagnosing malignancy.
p values less than 0.05 were considered statistically signiﬁcant.
All statistical calculations were done using computer program
SPSS (Statistical Package for the Social Science; SPSS Inc.,
Chicago, IL, USA) version 15 for Microsoft Windows.
Results
71 patients with diagnosed NSCLC (8 females and 63 males)
and 25 control cases (5 females and 20 males) were subjected
to the study, there is no statistical signiﬁcance between the con-
trol group and the study patients in the age, gender, smoking
habits and BMI as seen in Table 1, 56 patients (78.87%) pa-
tients were diagnosed by bronchoscopic biopsies, 11 patients
(15.49%) by either thoracoscopy or mediastinoscopy and 4 pa-
tients (5.63%) by open thoracotomy. Different histopatholo-
gical subtypes of NSCLC were categorized as squamous cell
carcinoma 31 (43.6%), adenocarcinoma 25 (35.2%) alveolar
cell carcinoma 9 (12.6%) and the other groups of NSCLC
including undifferentiated subtypes and unclassiﬁed cases 6
(8.4%).
Table 1 Patient and control clinical characteristics.
Patients Control p Value
Age (year) mean ± SD 60.2 ± 7.8 56 ± 8.8 >0.05
Gender Males n (%) 63 (88.7%) 20 (80%) >0.05
Females n (%) 8 (11.3%) 5 (20%) >0.05
Smoking habit Current smokers n (%) 45 (63.4%) 12 (48%) >0.05
Ex-smokers n (%) 12 (16.9%) 3 (12%) >0.05
Non-smokers n (%) 14 (19.7%) 10 (40%) >0.05
BMI mean ± SD 26.6 ± 2.5 27.2 ± 2.0 >0.05
Method of diagnosis Bronchoscopy n (%) 56 (78.87%)
Thoracoscopy or mediastinoscopyn (%) 11 (15.49%)
Thoracotomy n (%) 4 (5.63%)
Serum CRP (mg/dl) mean ± SD 114.2 ± 60.1 13.4 ± 8.6 <0.001
Serum PCT (ng/ml) mean ± SD 0.22 ± 0.15 0.23 ± 0.16 >0.05
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Figure 2 Box plots showing CRP levels in patients with non-
small cell lung cancer and control group 110 (17–155) mg/dl and
10 (3–33) mg/dl; p< 0.001.
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the control group as regards PCT level 0.22 ± 0.15 ng/ml vs.
0.23 ± 0.16 ng/ml p value > 0.05 Fig. 1 indicating the absence
of bacterial infection in both groups. Also No signiﬁcant dif-
ferences were evidenced when comparing the PCT concentra-
tion values of NSCLC patients according to different patient
characteristics and tumor stages. All PCT levels in the patient
group as well as the control group were below the cutoff point
for the test which is 0.5 ng/ml.
The serum CRP was statistically higher in the patient group
compared to the control group (114.2 ± 60.1 mg/ml vs.
13.4 ± 8.6 mg/ml) with p value < 0.001 Fig. 2. The serum
CRP level was studied according to patients with different his-
to-pathological subtypes of NSCLC, the stage of the disease
and tumor size, data are summarized in Table 2, mean serum
CRP values for subtypes were 159.87 ± 58.45 mg/dl for squa-
mous cell carcinoma, 137.88 ± 61.2 mg/ml for adenocarci-
noma 155.00 ± 74.869 mg/ml for alveolar cell carcinoma and
127.83 ± 54.92 mg/ml for group entitled under others with p
value more than 0.05 as shown in Fig. 3.
Different subtypes of NSCLC were compared as regards
serum CRP and the results did not show statistical signiﬁcance
shown in Table 2 and Fig. 3.
The size of the primary lesion in the patient group was ana-
lyzed and the correlation between the size and the level of ser-
um CRP showed a positive linear relationship with a r< 0.5
and a p value > 0.05 as shown in Fig 4.0.23 0.22 
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Figure 1 Median procalcitonin (PCT) level in the patient and
control groups with no statistically signiﬁcant difference (p
value > 0.05).In the patient group the tumors were further classiﬁed
according to the TNM classiﬁcation into stage 1A, 1B, 2A,
2B, 3A, 3B, and 4, none of the tumors was found in stage
1A, 2 (2.8%) stage 1B, 8.5% stage 2A, 15.5% stage 2B,
19.7% stage 3A, 38% stage 3B, and 15.5% stage 4, the com-
parison of mean maximum and minimum CRP among differ-
ent stages of NSCLC did not reach a statistically signiﬁcant
value (Figs. 5 and 6).
Discussion
In this study the main ﬁnding is the presence of a signiﬁcant
increase of the CRP level among patients with NSCLC com-
pared to control subjects and there was no signiﬁcant differ-
ence in the serum procalcitonin level indicating that the rise
of CRP in the patient group was not related to infectious eti-
ology. Serum procalcitonin is seen higher in patients with ac-
tive bacterial infection and there is no available data in the
literature to support rise of PCT in various cancer patients
so it was used to exclude patients with lung cancer associated
with infectious etiology. Procalcitonin as a more sensitive test
than CRP for bacterial infections was reviewed in different
studies [15].
Serum CRP levels, measurement of which is relatively inex-
pensive and easy to quantify in daily clinical practice and it is
used in various studies to diagnose, evaluate the prognosis or
response to treatment. In general, patients with cancer have
Table 2 Serum CRP levels (mg/dl) for different subtypes of NSCLC, tumor stage according to TNM classiﬁcation, and tumor size
(size less than or equal to 7 cm was taken as cutoff as mean size).
n (%) CRP mean ± SD (mg/ml) p Value
Tumor type Squamous cell carcinoma 31 (43.6%) 159.87 ± 58.45 >0.05
Adenocarcinoma 25 (35.2%) 137.88 ± 61.2
Alveolar cell carcinoma 9 (12.6) 155.00 ± 74.86
Others 6 (8.4%) 127.83 ± 54.92
Tumor stage (TNM) 1B 2 (2.8%) 53.52 ± 13.3 <0.001
2A 6 (8.5%) 44.85 ± 16.61
2B 11 (15.5%) 65.53 ± 38.57
3A 14 (19.7%) 110.33 ± 53.37
3B 27 (38%) 155.85 ± 65.71
4 11(15.5%) 170.05 ± 60.50
Tumor size Size 6 7 cm 52 (73.2%) 110.27 ± 69.55 <0.001
Size > 7 cm 19 (26.7%) 167.38 ± 53.80
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Figure 3 CRP level in different subtypes of non-small cell lung
cancer (NSCLC) showing non-statistical signiﬁcant difference
(p> 0.05).
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Figure 4 Scatter diagram for the correlation coefﬁcient between
tumor size (horizontal axis) and serum CRP level (vertical axis)
showing a signiﬁcant linear relationship (r= 0.509, p< 0.05).
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Figure 5 Serum CRP levels in patient group as classiﬁed
according to TNM (with median maximum and minimum values).
720 H. Aref, S. Refaatbeen shown to have higher CRP concentrations than healthy
controls and participants with some benign diseases [16].
The elevated serum CRP is strongly related to risk of
cancers especially lung cancer in a recent meta-analysis study
by Yong-Guo et al. [17], and it was not known whether theelevation of CRP represents a carcinogenic effect participation
or that the elevated CRP is a tumor marker itself.
Several possible mechanisms have been proposed for the
relationship between CRP and cancer. First, tumor growth
can cause tissue inﬂammation and hence increase CRP levels
[18,19]. Second, CRP could be an indicator of an immune
response to tumor antigens [20–22]. Third, there is evidence
that cancer cells can increase the production of inﬂammatory
proteins, which could explain the high CRP concentrations
in patients with cancer. Some cancerous cells have been shown
to express CRP [23–25]. And cancer cell lines have been shown
to secrete IL6 and IL8, which in turn induce the production of
CRP [26,27]. These mechanisms imply that increased CRP is a
response to the neoplastic process and that CRP concentra-
tions could thus provide a marker for identifying people with
cancer at an early stage when treatment might be more
effective. Finally, chronic inﬂammation, of which CRP is an
important marker, might have an etiological role in cancer.
This last factor has not been included in the present study by
performing serum procalcitonin level to all patients and
excluding them if the test is positive.
In this study we found there is a positive correlation
coefﬁcient between serum CRP level and pathologic tumor
diameter, we selected 7 cm as a mean tumor diameter in our
study and the serum CRP level for tumors with a diameter
higher than 7 cm was statistically higher (167.38 ± 53.80 vs.
y = 29.38x - 11.53 
r = 0.4032
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Figure 6 Levels of CRP in different stages of NSCLC according to TNM classiﬁcation, 1 = stage1B, 2 = stage 2A, 3 = stage 2B,
4 = stage 3A, 5 = stage 3B, 6 = stage 4 (r= 0.403 and p value < 0.05).
CRP evaluation in non-small cell lung cancer 721110.27 ± 69.55 p value < 0.001), this is matching with a study
done by Lee et al. [28] in surgically resected specimens showing
increased CRP level with lymphovascular spread and patho-
logic tumor size, on the contrary Lee et al. found a higher ser-
um level with squamous cell carcinoma versus non-squamous
cancer which we could not prove in the present study. Tulek
et al. also did not ﬁnd a correlation between tumor patholog-
ical subtype and CRP level.
In this study we found a positive correlation between the
CRP level and the tumor stage (p value < 0.001), a ﬁnding
which was present in a study that demonstrated a relationship
between tumor diameter and higher level of CRP but weakly
[29].
Most of the studies attempting to evaluate the use of circu-
lating CRP in the diagnosis of various cancers did not present
relevant statistical analyses and most of the vast literature pub-
lished on the association of circulating CRP with cancer are
based on studies of prevalent cancer cases [6], which cannot
provide evidence for causality but different studies support
the poor prognosis when patients with NSCLC [30] or small
cell lung cancer [31] show a high serum CRP level. As shown
in the present study there was a statistically signiﬁcant higher
level of CRP associated with advanced stages of NSCLC and
also with larger tumor size, indicating poorer prognosis.
The elevation of CRP is not known to be either related to the
tumor itself or increased with size and stage as shown in this
study or it is related to the nature of the patient who develops
NSCLC as some studies [4] showed elevated CRP as a risk fac-
tor for carcinogenesis, which support a role of chronic inﬂam-
mation in carcinogenesis. But based on current knowledge,
baseline CRP measurement is not recommended for the predic-
tion of cancer incidence and cancer screening. Further studies
are needed to identify whether CRP, as a marker of inﬂamma-
tion, has a direct role in carcinogenesis. But the response to che-
motherapy was shown to be inferior in patients with higher
pretreatment levels of CRP indicating poorer prognosis [32],
and the same was seen in surgical resection of NSCLC cases
with high pre-operative CRP compared to low CRP [33].
The weak points in this study are the small number of pa-
tients and the study is done on already diagnosed cases which
do not reﬂect the actual clinical practice, but it can be used as a
tool to predict the prognosis toward chemotherapy or
operability.In conclusion, CRP is an inﬂammatory biomarker that is
shown to be elevated in NSCLC and its elevation is correlated
with the tumor size and tumor staging but not to subtypes of
NSCLC, it may point to poor outcome and poorer prognosis.
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